Takamori Shinkichi, Toyokawa Gouji, Okamoto Isamu, Takada Kazuki, Kozuma Yuka, Matsubara Taichi, Haratake Naoki, Akamine Takaki, Katsura Masakazu, Mukae Nobutaka, Shoji Fumihiro, Okamoto Tatsuro, Oda Yoshinao, Iwaki Toru, Iihara Koji, Nakanishi Yoichi, Maehara Yoshihiko
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Anticancer Res. 2017 Aug;37(8):4223-4228. doi: 10.21873/anticanres.11813.
To investigate the discordance in the programmed cell death-ligand 1 (PD-L1) expression between primary and metastatic tumors and analyze the association between the discordance and the clinical factors in non-small cell lung cancer (NSCLC) patients.
Twenty-one NSCLC patients who underwent surgery or biopsy for paired primary and metastatic lesions at our Institution from 2005 to 2016 were analyzed. Lesions with the PD-L1 expression being ≥5% were considered PD-L1-positive.
The metastatic sites included the brain (n=16), adrenal gland (n=3), spleen (n=1) and jejunum (n=1). Negative conversion of the primary PD-L1-positive NSCLC and positive conversion of the primary PD-L1-negative NSCLC were observed in 3 (14%) and 2 (10%) cases, respectively. Radiotherapy for the metastatic brain lesion before its resection showed a significant relationship with the positive conversion of the primary PD-L1-negative NSCLC (p=0.048).
Radiotherapy-derived effects may contribute to the positive conversion of the primary PD-L1-negative NSCLC.
研究非小细胞肺癌（NSCLC）患者原发性肿瘤与转移瘤之间程序性细胞死亡配体1（PD-L1）表达的不一致性，并分析这种不一致性与临床因素之间的关联。
分析了2005年至2016年在本机构接受手术或活检以获取配对原发性和转移性病变的21例NSCLC患者。PD-L1表达≥5%的病变被视为PD-L1阳性。
转移部位包括脑（n = 16）、肾上腺（n = 3）、脾（n = 1）和空肠（n = 1）。原发性PD-L1阳性NSCLC出现阴性转换和原发性PD-L1阴性NSCLC出现阳性转换的病例分别有3例（14%）和2例（10%）。转移性脑病变在切除前接受放疗与原发性PD-L1阴性NSCLC的阳性转换显著相关（p = 0.048）。
放疗产生的效应可能导致原发性PD-L1阴性NSCLC出现阳性转换。
